The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
GAVRETO (Roche Products Pty Ltd)
Product name
GAVRETO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
242 (255 working days)
Active ingredients
pralsetinib
Registration type
NCE/NBE
Indication
Non-Small Cell Lung Cancer (NSCLC)
Gavreto has provisional approval in Australia for the treatment of adult patients with locally advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The decision to approve this indication has been made on the basis of overall response rate (ORR) and duration of response (DOR) in single-arm trials. Continued approval of this indication depends on verification and description of benefit in confirmatory trials.